Equity Overview
Price & Market Data
Price: $3.51
Daily Change: +$0.21 / 5.98%
Daily Range: $3.42 - $3.58
Market Cap: $1,000,429,568
Daily Volume: 13,166
Performance Metrics
1 Week: 0.61%
1 Month: -4.35%
3 Months: -3.79%
6 Months: -44.07%
1 Year: 60.98%
YTD: -3.51%
Company Details
Employees: 562
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.